Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab + R-CHOP in ctDNA high-risk untreated DLBCL
NL-OMON56027Phase 2Recruiting
- Sponsor
- Roche
- Start
- Oct 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and follicular lymphoma, transformed (t-FL), sponsored by Roche. Primary endpoint: End-of-treatment complete response rate. Started Oct 2022; status: recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma, transformed (t-FL)
Beyond the preview
Go deeper on NL-OMON56027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56027.